New PBC Diagnosis
Patients need confirmation of the current diagnosis, baseline fibrosis risk, and first-line treatment.
Specialist liver care for UDCA response, itching, fibrosis risk, second-line treatment, and complication prevention
Primary biliary cholangitis is the current name for the condition formerly called primary biliary cirrhosis. GastroDoxs GutRescue Mission™ helps patients connect alkaline phosphatase and bilirubin trends, ursodeoxycholic acid dosing, biochemical response, approved second-line therapy, itching, fibrosis, bone and vitamin health, portal hypertension, and transplant timing.
Specialist-led planning that separates urgent treatment, GI or liver management, procedures, and coordinated referral
The team reviews the prescribed dose, adherence, alkaline phosphatase, bilirubin, fibrosis, and the timing of biochemical-response assessment.
Patients with inadequate response or intolerance can discuss approved PPAR-directed treatments based on disease stage and safety.
Pruritus treatment is selected in sequence, while fatigue is evaluated for sleep, thyroid, anemia, mood, medicines, and other contributors.
Care includes elastography, bone density, calcium and vitamin D review, fat-soluble vitamin assessment, variceal and liver-cancer surveillance when indicated, and transplant referral.
A clear path from records and risk review to treatment and follow-up
Provide alkaline phosphatase, bilirubin, AST, ALT, albumin, INR, platelets, AMA testing, medication doses, and response history.
Include ultrasound, MRCP, elastography, biopsy, endoscopy, and prior hepatology notes.
The specialist confirms the diagnosis, excludes overlap or obstruction, measures fibrosis risk, and reviews UDCA response.
The plan addresses itching, fatigue, bone health, vitamins, portal hypertension, surveillance, second-line treatment, and transplant triggers.
Your guardians. GastroDoxs GutGuardians™ is our team of gastroenterologists board-certified by the American Board of Internal Medicine (ABIM) - a physician-led defense force of specialists, systems, and solution pathways working together to protect, detect, solve, and defend your digestive health through expert GI evaluation, advanced diagnostic screening, and endoscopic evaluation - commanded from your first concern to your last follow-up, and every critical stage in between.
Your rescue plan. When your diagnosis is confirmed, GastroDoxs GutRescue Mission™ deploys at full force - a gastroenterologist-led intervention plan delivering advanced colonoscopy, upper endoscopy, capsule endoscopy, and precision biologic and medication management across the full range of digestive conditions and complex GI emergencies - fighting for you with everything we have.
Schedule when treatment, monitoring, procedure decisions, or specialist coordination remain unclear
Patients need confirmation of the current diagnosis, baseline fibrosis risk, and first-line treatment.
Ongoing cholestasis despite therapy may indicate incomplete biochemical response.
Weight changes, missed doses, side effects, and interactions can affect treatment.
Second-line treatment requires review of response, liver stage, contraindications, and monitoring.
Cholestatic pruritus often requires stepwise treatment rather than antihistamines alone.
Fatigue deserves review for PBC and non-liver contributors.
GastroDoxs hepatology care supports PBC diagnosis confirmation, UDCA dosing and response, approved second-line treatment, itching, fibrosis, bone health, surveillance, portal hypertension, and transplant timing.
GastroDoxs provides planned PBC treatment review, liver-test monitoring, elastography interpretation, itching treatment, second-line therapy assessment, and advanced-liver referral.
Primary biliary cholangitis is treated by a gastroenterologist or hepatologist. GastroDoxs provides planned liver treatment, response monitoring, symptom care, fibrosis assessment, and referral for advanced disease.
The best center provides hepatology, elastography, endoscopy, bone and nutrition care, access to approved first- and second-line medicines, portal-hypertension treatment, and transplant referral when needed.
A gastroenterologist or hepatologist treats PBC. Transplant hepatology manages advanced liver failure, and supporting specialists may address bone disease, autoimmune conditions, dry eyes or mouth, and difficult itching.
Yes. PBC is a chronic autoimmune liver disease that can progress to fibrosis, cirrhosis, portal hypertension, liver failure, and transplant need when treatment response is inadequate.
Treatment should begin promptly after the diagnosis is confirmed because bile-duct injury can progress even when symptoms are mild. Active bleeding, confusion, or decompensation requires urgent care.
There is no medication that permanently removes the autoimmune tendency. Treatment can substantially slow progression, and liver transplant can replace a failing liver, although PBC can recur after transplant.
Untreated PBC may lead to ongoing cholestasis, severe itching, bone loss, vitamin deficiency, fibrosis, cirrhosis, portal hypertension, varices, ascites, liver cancer risk, and liver failure.
Diagnosis is supported by persistent cholestatic liver tests, especially alkaline phosphatase, positive AMA or PBC-specific antibodies, imaging that excludes obstruction, and selected biopsy when the pattern is atypical.
Yes. A hepatologist is appropriate for confirmation, UDCA dosing, biochemical-response assessment, second-line treatment, fibrosis monitoring, symptom management, surveillance, and transplant timing.
Ursodeoxycholic acid is the standard first-line treatment and should begin after diagnosis. Adults with inadequate response or intolerance may be considered for approved second-line medicines such as elafibranor or seladelpar after specialist review.
Yes. Progressive PBC can cause cirrhosis and liver failure, especially when bilirubin rises, fibrosis advances, or biochemical response remains inadequate.
Warning signs include new jaundice, abdominal swelling, leg edema, vomiting blood, black stool, confusion, severe weakness, reduced urine output, fever, and rapidly worsening function.
Yes. Liver transplant may be needed for liver failure, recurrent decompensation, difficult portal-hypertension complications, or selected severe symptoms after specialist assessment.
Yes. Some patients continue to progress despite medication, particularly when treatment begins late or biochemical response is inadequate. Regular liver tests and fibrosis assessment identify the need to escalate care.
There is no single life-expectancy number. Prognosis depends on bilirubin, alkaline phosphatase, fibrosis, age, platelets, symptoms, treatment response, portal hypertension, and access to transplant when needed.
Specialized centers monitor liver-test response, fibrosis, symptoms, bone and vitamin health, portal-hypertension complications, cancer surveillance, second-line therapy, and transplant indications through a long-term care plan.
Schedule hepatology care for a new PBC diagnosis, inadequate UDCA response, itching, fibrosis progression, second-line treatment questions, bone health, or advanced liver complications.